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Summary Lymphoma-associated antigen (LAA) was isolated from lymph nodes of confirmed Hodgkin's and
non-Hodgkin's lymphomas by saline extraction, centrifugation and ammonium sulphate fractionation and
then purified by G-200 Sephadex chromatography which revealed its mol.wt at 29K daltons. By sucrose
density-gradient centrifugation the mol.wt of LAA was 43K daltons. Physicochemical properties of LAA
were determined. In polyacrylamide gel LAA separated as a discrete protein with electrophoretic mobility of
a-globulin at pH 8.6. The pI was 5.04 and sedimentation coefficient between 3S-4S. Xenogeneic antiserum
was raised in rabbits and purified by cross adsorption and affinity chromatography. By immunochemical
methods, LAA was detected in the sera and body fluids of most lymphoma patients and was absent from
normal individuals and patients with other types of cancer. A radioimmunoassay procedure was developed
and preliminary studies revealed that the lymphoma sera at 1:5 and 1:10 dilution inhibited the binding of
labelled LAA by antibody, whereas the sera of normals and controls exhibited no such inhibition. The
sensitivity of this assay was 22ngml-1. The serum LAA levels were in the range of 187-15OOngmlP . These
results were also confirmed by the indirect inhibition assay using conjugated peroxidase. Serial determination
of serum LAA by RIA indicated a positive correlation with the course of disease.
The early diagnosis of asymptomatic cancer is an
important aim. Recent advances in technology have
revolutionised methods of diagnosis.
Immunodiagnosis has gained importance during the
past decade. There have been several reports on the
synthesis and secretion of cell surface markers and
immunoassay procedures have been evolved for the
detection of these antigens. Tumour-associated
antigens have been reported for many human
cancers such as colonic carcinoma, melanoma,
hepatoma and leukaemia. (Gold & Freedman. 1965;
Morton et al., 1968; Tatarinov, 1964, Greaves,
1979). The identification and isolation of an antigen
associated with Hodgkin's disease has been
reported by Order et al. (1973). Subsequently
several antigens elaborated by T and B cells and
their subpopulations have been reported in the
blood and tissue of patients with lymphoid
neoplasms. However, no specific serological test has
yet been evolved for the early detection of
malignant lymphomas.
About 5% of all malignant disease treated at the
Cancer Institute Madras, India are lymphomas and
>50% of the cancers in children are malignant
lymphomas. Occasionally the signs and symptoms
are minimal or equivocal: likewise, the histology is
sometimes inconclusive due to lack of
representative specimens or inaccessibility of the
small lymph nodes. A serological test for these
patients may facilitate early detection of
lymphomas. This paper describes the isolation and
partial characterization of a lymphoma-associated
antigen (LAA); the development of an antiserum in
rabbits and the evaluation of an immunodiagnostic
test.
Clinical material
Fresh biopsies of lymph nodes were obtained at
surgery from 42 patients, the WHO histological
classification of which is listed in Table I (Mathe et
Table I Lymph node biopsies
Histological No.
Classification Stage cases
Hodgkin's Disease 14
a. Lymphocyte depletion II,IIB,III 4
b. Lymphocyte predominance IV, III 2
c. Nodular sclerosis IIA 4
d. Mixed cellularity II,IIB,III,A,B 4
Non-Hodgkin's Lymphoma 28
a. Lymphocytic
Poorly-differentiated
(Lymphoblastic) III,IIIB,IV 5
b. Lymphocytic-well
differentiated (small round
lymphocytes) IA,III,IIB 8
c. Lymphocytic intermediate
differentiation (small
follicle lymphocytes) I,IV 10
d. Large lymphoid cells
(undifferentiated large
cells) 5
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al., 1976). Traces of blood adhering to the tissues
were removed, connective tissue was dissected out
and the specimens stored at -20°C. Spleens from
lymphoma patients were used for isolation of
antigen. Biopsies of other cancers and their lymph
nodes were stored frozen.
Blood specimens were obtained from controls
and patients in a fasting condition and the fresh
sera used for immunological studies, Urine, CSF,
gastric fluid and saliva were also studied Aliquots
of 24h urine specimens were dialysed against water
at 40C and concentrated before analysis.
Reagents
Sephadex G-200, G-25, G-75, Sepharose-4B were
obtained from Pharmacia Fine Chemicals, Uppsala,
Sweden, Ionagar from Oxoid, U.K., chloramine T,
BSA fraction V(RIA grade), PEG, FITC, BSA, egg
albumin, cytochrome C, chymotrypsin from Sigma
Chemical Cy, USA. Radioactive 125I carrier free, as
sodium iodide from Amersham, U.K. and all other
chemicals were ofhigh grade from BDH, U.K.
Preparation oflymphoma-associated antigen (LAA)
The LAA was isolated using a modified procedure
of Akira et al. (1968) and all procedures were
conducted at 0°C. The tumour tissues (lymphomas
and other types of cancers) were homogenised in
0.15 M saline for 5min. The homogenate was
centrifuged at 1000g for 20min and the
supernatant discarded. The sediment was ground
with quartz sand, extracted with 25ml, 0.15M
saline and centrifuged. The extraction was repeated.
three times, the extracts pooled and centrifuged at
10,000g for 15min. The supernatant was adjusted
to pH 4.5 and allowed to stand for 15min. The
protein in the clear solution was partly precipitated
by adding AmSO4 to 50% saturation, stirring
constantly and allowed to stand for 2h. At this
saturation the insoluble interfering proteins were
precipitated and the soluble lymphoma antigen
remained in solution and was separated by
centrifugation at 5000g for 15min. The clear
supernatant was dialysed against distilled water for
24h, concentrated by dialysis against 30% PVP and
stored at -200C using sodium azide as
preservative.
Purification of LAA:-LAA was purified by gel
filtration on Sephadex G-200 (50 x 1.5cm) column
previously equilibrated with Tris-HCl buffer pH 7.5
containing 0.1 M KCI and eluted with the same
buffer. Two ml fractions were collected and assayed
for protein by the Lowry method. The fractions
were pooled, dialysed against PVP and lyophilized.
Reference compounds BSA, egg albumin,
Cytochrome C and chymotrypsin were also eluted
from the same column under identical conditions
for mol.wt calibration.
Physicochemical characterization ofLAA
The homogeneity and electrophoretic mobility of
LAA were determined by rod gel electrophoresis
according to the procedure of Davis (1964) in 7.5%
polyacrylamide gel using 0.05M borate buffer pH
8.6 as running buffer and compared with serum
from lymphoma patients and human ferritin. The
electrophoresis was carried out with a current of
4mA per tube for 2h. After the run one gel of
LAA was stained with amido black, another one
with potassium ferrocyanide and a third one with
periodic acid Schiff reagent.
Isoelectric focusing ofLAA:-The homogeneity and
pl of LAA were determined by the method of
Leaback (1975). Isoelectric focusing was carried out
for 1.5h with a power supply of 25W at 10°C in
flat beds of gels containing pH gradients of 3-10
and 3.5-5.2 (LKB ampholine). Ferritin and
thryoglobulin were used as standards. After the
run, pH was measured using LKB glass electrode
and the gel was stained using Coomassie Brilliant
Blue.
Molecular weight ofLAA:-The mol.wt ofLAA was
also determined by sucrose gradient centrifugation.
Five-20% sucrose gradient was prepared using an
LKB-ultragrad gradient maker in Sml polyallomer
tubes. Two hundred M1 of the standard proteins
(2mgml- 1) were used in addition to the sample.
The tubes were sealed in a Sorvall TV-865 ultra
vertical rotor and spun at 45,000rpm for 2h at 4°C
in a Sorvall OTD-75B ultracentrifuge. Protein
concentration of each fraction was determined by
measuring the absorbance at 280nm. The
sedimentation coefficient of the standard and of
LAA were determined using the sedimentation
estimation aid chart.
Preparation ofLAA antiserum
In-bred, 6-8 months old rabbits were immunized.
The antigen was injected s.c. once a week for 5
weeks (1-5mg protein) with an equal volume of
complete Freund's adjuvant. The rabbits were bled
10 days after the last injection. Two weeks later,
the animals were rechallenged with 1 mg of the
antigen and 7 days later blood was collected. The
sera were absorbed with homogenates of normal
lymphoid tissue, normal RBCs and foetal serum.
The antiserum was purified by absorption with
pure antigen conjugated to an activated Sepharose
4B column. Conjugation was carried out by aLYMPHOMA-ASSOCIATED ANTIGEN 719
modified procedure of Porath et al. (1967). The
loaded column (8-10°C) was washed with 3 column
volumes each of borate buffer, Tris-HCI-NaCl
buffer, 0.25M acetic acid and Tris buffer, pH 7.6.
Two ml of antiserum per gram Sepharose 4B was
loaded to the column which was flushed with Tris
buffer (flow rate, 15-18mlh-1). The eluate was
collected, and the tubes monitored at 280nm. The
specific antibody was eluted from the column with
0.25 M acetic acid and neutralized with a saturated
sodium bicarbonate solution. Each fraction was
examined for antibody by gel diffusion, the
fractions pooled, dialysed and lyophilized.
Immunological studies ofthe LAA antiserum
The antibody was examined for its specificity
against the antigenic material (LAA) by the
following techniques: Agar gel:-diffusion: The
immunodiffusion was carried out in slides
containing 1 mm 1.5% ionagar in distilled water
containing 0.5% solution of sodium azide
(Ouchterlony, 1949). The slides were incubated at
37°C for 3h in a moist chamber and examined after
washing in saline overnight and staining with 0.5%
tannic acid.
Counter electrophoresis:-Counter electrophoresis
was carried out using 0.05M veronal buffer pH8.6
and agar gel (1% in veronal buffer) for 1 h with a
voltage of 6 volts cm-1 applied across the plate.
The plates were washed and stained with 0.5%
tannic acid.
Immunoelectrophoresis:-Immunoelectrophoresiswas
performed in 0.08 M veronal buffered (pH8.6) 1%
ionagar at 7-8 volts cm-l for 30min and diffusion
allowed to take place at 37°C for 24h. The plates
were stained as described above.
Antibody titre:-The antibody titre was determined
by passive haemagglutination inhibition assay using
tanned sheep erythrocytes (SRBC) coated with
LAA. 2.5% SRBC suspension in PBS, pH 7.2 was
treated with 0.005% tannic acid in saline, and
incubated at 36°C for 10min. The cells were
separated, washed and made up to suitable volume
with PBS. One ml of LAA solution (2mgml 1) was
treated with 4ml PBS and 1 ml of tanned SRBC
suspension, mixed gently and kept at room
temperature for 10min. Control cell suspension was
prepared using normal lymphoid tissue instead of
LAA solution.
Normal rabbit serum inactivated at 56°C was
used as diluent (1:100) The assay was carried out in
microtitre plates, One hundred p1 of the diluent was
transferred to a series of wells and 100p1 of
antiserum was added to the first well and serially
diluted by aspirating 100p1 of the content, Twenty
p1 of tanned LAA coated SRBC was added to each
well, the plate was incubated at 37°C for 2h.
Radioiodination ofLAA
The radioiodination of LAA was carried out using
chloramine T technique of Hunter (1967).
Purification oflabelled LAA
The protein fraction was mixed with an equal
volume of fresh human normal plasma and labelled
LAA eluted from a Sephadex G-75 column
equilibrated with barbitol buffer. Two peaks
appeared in the eluate. The second peak,
representing intact LAA, was diluted with
phosphate buffer containing 5% BSA so that 0.1 ml
of the solution had a protein concentration of 60-
100ng of LAA and a count of 10,000CPM.
Radioimmunoassay
The radioimmunoassay was performed according to
the method of Yallow & Berson (1960). Into Sml
polypropylene tubes were placed 0.1 ml borate
buffer 0.04M, pH 7.4, containing standard LAA
(3.12-100ng). 0.1 ml aliquots of the diluted
unknown samples were added to sample tubes:
blank and reference (NSB) were prepared by the
addition of only the label or label and antibody.
The assay was run in duplicate. Antibody (0.1 ml)
at 1/1000 dilution, yG carrier protein (0.1 ml) were
added followed by 0.1 ml of labelled LAA
(10,000CPM). After incubating at 20°C for 18h the
antibody-bound antigen was precipitated by adding
1 ml 20% PEG. The tubes were centrifuged
(3,300rpm, 20min), the supernatant was decanted
and the precipitate counted in a gamma counter.
LAA content of unknown samples was determined
by interpolation from the standard binding
inhibition curve (spline function curve).
Solid phase enzyme labelled immunosorbent
assay:-The serum LAA levels were determined by
the indirect inhibition assay of Marren (1978). The
wells in the titre plates were coated with LAA
(5mgml-1 protein) and diluted sera samples (1:5,
1:10) were added to different wells and incubated
with 0.05ml of antibody (1/800) at 37°C for 30min.
The plates were washed with PBS, Tween 20
reagent, and 0.1ml of 1% orthophenylenediamine
containing 3% hydrogen peroxide was added to
each well and the plates were kept at 37°C for
30min. The reaction was arrested by adding 0.1ml
of 2/3N sulphuric acid and measured at 490nm.720 M. UDAYACHANDER et al.
T and B cell distribution in malignant lymphoid
tissue
The T/B cell distribution of the disaggregated
lymph nodes of patients was determined by E-
rosette formation and detection of surface
immunoglobulin respectively.
Results
Figure 1 illustrates the elution profile of LAA from
sephadex G-200 column. There were 3 main peaks:
the immunoreactive fractions of the second peak
were pooled and concentrated to obtain a solution
of 5mgml- protein. In polyacrylamide gel LAA
separated as a discrete protein with electrophoretic
mobility of an a-globulin. LAA was not stained by
potassium ferrocyanide and hence is not an iron
protein. These results revealed that LAA is not
ferritin which exhibited a slow cathodic mobility.
The non-reactivity of human ferritin with anti-LAA
confirmed these results. LAA was not stained by
the PAS reagent and hence is not a glycoprotein.
LAA isolated from lymph nodes, spleen and urine
of lymphoma patients was found to be identical
with a pI 5.04. Calibration markers were eluted
from G-200 column under identical conditions and
the calculated mol.wt of LAA was 29K daltons.
Using 5-20% sucrose gradient, the mol.wt was
43 K daltons with a sedimentation coefficient of 3S-
4S.
Using the pure LAA as antigen, antiserum was
prepared and purified by conventional methods. By
passive haemagglutination inhibition assay, the
antibody titre was found to vary from 250-1000.
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The antiserum reacted with the antigenic material
forming a single discrete band by agar gel diffusion,
immunoelectrophoresis and counter electrophoresis
indicating the presence of a specific antibody
(Figure 2). The Ouchterlony diffusion test (LAA
test) was positive for most of the sera of patients
with confirmed Hodgkin's disease or NHL. The
lymphoma serum showed a line of identity with the
tissue antigen. LAA was detected in urine, CSF,
saliva and gastric fluid of a few lymphoma patients.
The test was negative for normals and patients with
non-malignant lymphadenitis. However, with the
sera from different types of cancers there were few
false positive results in breast, stomach and tonsil
cancer and leukaemia (Table II). The antiserum did
not react with the tissue extracts of various other
types of cancers. More than 50% of the malignant
lymphomas were of B-cell type (surface immuno-
globulin positive). The specificity of the LAA test
was also examined by a double blind trial which
gave a 98% positive result. Of the 120 unknown
sera analysed which included normal individuals,
controls and lymphonas there were no false
negatives. Of the 3 false positive results, 2 were
advanced malignancies, one of stomach and the
other of tonsil.
The LAA test was positive in a few patients with
vague symptoms such as low grade fever, general
malaise, weight loss without any palpable lymph
nodes, 6-9 weeks earlier than the histological
diagnosis. These suspected patients were followed
up by clinical examination, radiological and or
sometime marrow examination and the disease was
detected in the course of few months (Table III).
In patients with generalised lymphadenopthy, the
Fraction volume ml
Figure 1 Sephadex G-200 Chromatography (50 x 1.5cm) of crude extract of malignant lymph nodes eluted
with 0.05 M Tris-HCl buffer pH 7.5. Immunologically reactive to LAA antibody (------).LYMPHOMA-ASSOCIATED ANTIGEN 721
Figure 2 Ouchterlony immunodiffusion, immunoelectrophoresis and counter electrophoresis of anti-LAA
against LAA, human ferritin, sera, body fluids, tissue extracts of normals, patients. Immunodiffusion: 1. LAA,
2. Hodgkin's serum, 3. Lymphoma urine, 4. Gastric fluid, Reticulum cell sarcoma, 5. Ca. cheek serum, 6. Ca.
stomach serum, 7. Lymphadenitis serum, 8. Lymphosarcoma saliva, 9. Nodular sclerosis serum, 10. Ca. breast
serum, 11. Lymphosarcoma serum, 12. LAA, 13. Lymphoma urine, 14. Human ferritin, 15. Normal urine, 16.
Ca. breast tissue extract. Immunoelectrophoresis: 1. LAA, 2. Lymphoma serum. Counter electrophoresis: Wells
1'3'4'5'7'8' contain lymphoma sera, 9'LAA, 2' and 6' sera of normal and Ca. Cheek.722 M. UDAYACHANDER et al.
Table II Immunodiffusion of anti LAA against sera and body fluids of controls
and patients
LAA test result*
bodyfluids
No
tested Serum Urine CSF Saliva Gastric Fluid
Types ofcancers (specimen) P N P N P N P N P N
Normal controls 522BF 152 22 22 22 22
Lymphadenitis 7S 7
Hodgkin's disease lots 91 10 14 12 9 17 6 20 6 20
NHL 102SBF 91 11 14 7 12 9 5 16 12 9
Leukaemia
ALL 4BF 8 4 4 4 4 4
CLL 25
8BF
2 3 5 8 8 8
CML 20BF 2 18 20 20 20 20
Ca. stomach 28S 6 22 9 9 9 9
9BF
Ca. breast 48S 5 43 7 7 7 7 7BF ~ ~
Multiple myeloma 3BF 4 12 1 2 1 2 2 1 3
Ca. tonsil 7BF 2 5 7 7 7 7
Other types of 356S 356 43 43 43 43 cancers 43BF
S=Serum; BF=Body fluids; P=Positive; N=Negative.
*Numbers in each column=no. ofsamples tested.
Table III Lead time of LAA test*
Initial Duration Final
Patient histological follow up histological
no. diagnosis (months) diagnosis
1 No palpable
lymph node 2 Lymphocyte
depletion
2 Inconclusive 2.5 Lymphocyte
depletion
3 No palpable Mixed
lymph node 4 cellularity
4 No palpable Lymphocyte
lymph node 5 predominance
5 Inconclusive 2 Lymphocyte
depletion
6 Inconclusive 3 Nodular
sclerosis
*All patients presented with anaemia, low grade fever
and weight loss.
LAA test result correlated with the histological
diagnosis. The test was positive for lymphoma
patients and negative for patients with
lymphadenopathies due to other causes like
tuberculosis or metastatic cancer. By the gel
diffusion test with a sensitivity of 5-10 gml-' it
has been possible to differentiate between
lymphomas, other types of cancers and
lymphadenitis.
Development ofradioimmunoassay
The chloramine T method of Hunter was used for
the trace iodination of LAA. About 60% of added
1251 was incorporated as revealed by the peaks of
sephadex G-25 gel filtration (Figure 3). There were
two peaks, a protein peak and an iodine peak.
1/1000 dilution of the antibody gave 50% binding.
A linear relationship was observed between various
concentrations of LAA (3.12-100ngml-1) and theLYMPHOMA-ASSOCIATED ANTIGEN 723
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Figure 3 Purification of labelled LAA by Sephadex
G-25 gel filtration.
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Figure 4 Standard curve of enzyme-labelled immuno-
sorbent assay by indirect inhibition principle.
inhibition. The sensitivity of this assay was
15ngml- .
The sera of 17 normals and of 22 patients with
other types of cancers did not inhibit at a dilution
of 1:5 or 1:10 in this assay. The serum LAA levels
for 24 lymphoma patients were in the sensitivity
range of 187-1500 ngml-1. Similar results were
obtained by the ELISA assay (Table IV). The
standard inhibition curve was linear (Figure 4).
Serial determinations of serum LAA levels for
confirmed lymphoma patients showed a positive
correlation to the course of the disease (Table V).
Discussion
Using the xenogeneic antiserum raised in rabbits,
the presence of a circulating LAA in lymphoma
patients of T and B cell origin and of different
histological types has been demonstrated. LAA has
also been identified in the body fluids of lymphoma
patients. The LAA test is virtually negative for
normals and patients with various other types of
cancers. The few false positive results obtained for
non-lymphoid malignancies might be due to the
presence of closely-related antigenic determinants
present in the subpopulation of cells at different
stages of differentiation. Recent studies on cell
surface markers have shown a similarity between T
cell acute lymphoblastic leukaemias and T cell
lymphoblastic lymphomas (Nisson & Ponten, 1975;
Minowada et al., 1972). Immunological, cytological
and physicochemical features suggest that these two
lesions constitute a single disease process (Nathwani
et al., 1976; Pangalis et al., 1979). An LAA test
which is reactive for lymphoblastic lymphomas may
also be reactive for lymphoblastic leukaemias.
Neoplastic cells derived from a single clone and
residing in different anatomical compartments have
been found to possess identical surface markers
(Whiteside & Rowlands, 1977). Cell surface marker
analysis has been found to be of particular use in
determining whether the cytologically similar and
dissimilar lymphoid proliferation occurring in
different body sites are derived from the same
malignant clone or otherwise (Minowada et al.,
1980). The serum LAA of different histological
lymphomas may result from the same malignant
clone.
Neoplastic B cell proliferations are reported to be
heterogeneous with respect to SIg expression. Thus
Ia+SIg- and Ia+SIg+ cells may belong to the same
neoplastic clone and represent cells at different
stages of differentiation. This phenotypic
heterogeneity has been demonstrated in T cell-
derived malignant lymphoma also (Okamura et al.,
1981; Poppemma et al., 1981). From these studies it
is conceivable that a common antigen may exist for
the various phenotypes of lymphomas or it may be
that more than one binding site is present in the
antibody molecule, each specific for T cell and B
cell derived antigens or their subpopulations. This
warrants further study.
A negative reaction with tissue extracts of other
types of malignancies might indicate that LAA is
perhaps a determinant selectively expressed by
malignant lymphocytes.
The diagnostic potential of the LAA test appears
promising since in a few patients with generalised
lymphadenopathy, the test correlated well with
histological diagnosis. Also for patients with no
palpable lymph nodes the test had a lead time over
the histological confirmation of a few months.724 M. UDAYACHANDER et al.
Table IV Determination of serum LAA levels by RIA and ELISA for controls
and cancer patients*
Serum LAA level ngml-
Normals and types No. of
ofcancers cases RIA ELISA
Controls 17 Undetectable Undetectable
Hodgkin's Disease
Nodular Sclerosis 2 298,372 280,350
Lymphocyte depletion 4 568,734,1008,1500 524,698,930,1508
Lymphocyte predominance 3 328,294,505 272,255,496
Mixed cellularity 3 424,187,468 370,242,420
Non Hodgkin's lymphoma
Lymphocytic poorly
differentiated 3 770,483,442 715,440,395
Lymphocytic intermediate
differentiation 3 328,296,334 288,254,272
Lymphocytic well
differentiated 2 548,406 474,348
Large lymphoid cells 4 315,362,348,360 260,300,284,326
Other types of cancer 22 Undetectable Undetectable
*The estimations were done in duplicate. The values are mean of 4 estimations
of the same sample.
Table V Serial determinations of serum LAA levels for lymphoma
patients.* (Preliminary data)
Serum LAA ngml1
During At the
Patient Histological At treat- end of
no. Stage classification diagnosis ment therapy
1. I Lymphocytic well
differentiated 410 326 78
2. IV Large lymphoid
cells 830 570 115
3. II Lymphocytic poorly
differentiated 152 96 48
4. IV Lymphocyte
predominance** 948 438 124
5. 11 Lymphocyte
depletion** 288 115 64
6. II Lymphocytic well
differentiated 376 220 45
7. IIIB Lymphocytic poorly
differentiated 540 265 82
8. IV Lymphocytic intermediate
differentiation 664 476 180
9. II Large lymphoid
cells 760 378 148
*These patients were treated by combination chemotherapy.
**Hodgkin's disease.LYMPHOMA-ASSOCIATED ANTIGEN 725
The presence of an LAA-anti LAA system in
lymphomas has formed the basis for the
development of more sensitive and specific assay
procedures like RIA and ELISA for the early
detection of these cancers.
The lower limit of detection by RIA is 15ngml1
and the upper limit 0pgml-' and has a sensitivity
100-1000 times greater than the double diffusion
method. At this sensitivity range, LAA could not
be detected in the sera of normals and of patients
with other cancers. Hence this cut off may render
this test relatively selective for lymphomas. The
determination of serum LAA levels may serve as
useful clinical index to follow the course of the
disease. The serum LAA levels have been found to
fluctuate during chemotherapy: significantly
elevated levels observed initially fall gradually to
very low levels at the end of effective treatment as
seen from Table V.
Preliminary studies on the identification,
quantitation and clinical evaluation of LAA have
suggested the expression of a tumour-related
antigen by malignant lymphocytes and the potential
of this test for the detection of early malignant
lymphomas. These results are being confirmed by
preparing monoclonal antibodies to each
histological type of lymphoma by the hybridoma
technique of Kohler & Milstein as modified by
Kennett (1981).
The authors gratefully acknowledge the grants received
from the Council of Scientific and Industrial Research and
the Department of Science and Technology, New Delhi.
References
AKIRA, Y., MATUSUUNA, Y., CARPENTER, C.M. &
HYDE, L. (1968). Immunochemical studies on human
lung cancer antigens soluble in 50% saturated
ammonium sulphate. J. Natl Cancer Inst., 40, 663.
DAVIS, B.J. (1964). Disc electrophoresis II method and
application to human serum proteins. Ann. N.Y. Acad.
Sci., 121, 404.
GOLD, P. & FREEDMAN, S.O. (1965). Specific
carcinoembryonic antigens of human digestive system.
J. Exp. Med., 122, 467.
GREAVES, M.F. (1979). Immunodiagnosis of leukaemia In
Immunodiagnosis of Cancer Part I. p. 542 (Eds.
Herberman et al.) New York: Marcel Dekker, Inc.
HUNTER, W.M. (1967). The preparation of radioiodinated
proteins of high activity, their reaction with antibody
in vitro: the radioimmunoassay. In: Handbook of
Experimental Immunology, (Ed. Weir) Blackwell Sci.
Publ. Oxford, 608, 654.
KENNETT, R.H. (1981). Fusion protocols in Monoclonal
antibodies: Hybridomas: A new dimension in
biological analyses. p. 365, (Eds. Kennett & McKearn)
Plenum press. New York.
LEABACK, D.H. (1975). Isoelectric Focusing p. 201, (Eds.
Arbuthnott & Beeley) Butterworths. U.K.
MATHE, G., RAPPAPORT, H., O'CONOR, G.T. & TORLONI,
H. (1976). Histological and Cytological Typing of
Neoplastic Diseases of Haematopoietic and Lymphoid
Tissues. World Health Organisation, Geneva.
MARREN, G.E. (1978). Enzyme immunoassays. Tijdschrift
van de belgische vereniging van
laboratoriumtechnologen. Revue de l'Ass. Belge
Technol. Lab., 5, 199.
MINOWADA, J., SRIVASTAVA, B.I., FREEMAN, A.I. &
SANDBERG, A.A. (1980). Heterogeneity of Marker
profiles of 50 human leukemia lymphoma cell lines: A
model for hematopoietic cell differentiation. Proc. Am.
Assoc. Cancer Res., 21, 224.
MINOWADA, J., OHNUMA, T. & MOORE, G.E. (1972).
Rosette-forming human lymphoid cell lines. I
Establishment and evidence for origin of thymus-
derived lymphocytes. J. Natl Cancer Inst., 49, 891.
MORTON, D.L., MALMGREN, R.A., HOLMES, E.C. &
KETCHAM, A.S. (1968). Demonstration of antibodies
against human malignant melanoma by
immunofluorescence. Surgery, 64, 233.
NATHWANI, B.N., KIM, H. & RAPPAPORT, H. (1976).
Malignant lymphoma, lymphoblastic. Cancer, 38,
964.
NISSON, K. & PONTEN, J. (1975). Classification and
biological nature of established human haematopoietic
cell lines. Int. J. Cancer, 15, 321.
OKAMURA, S., CHECHIK, B.E., LEE, C., GELFAND, E.W. &
MAK, T.W. (1981). Heterogeneity of human
thymocytes and a malignant T-lympho-blast cell line.
Cancer Res., 41, 1664.
ORDER, S.E., CHIM, S.E. & HELLMAN, S. (1973).
Hodgkin's Disease associated antigen: Studies on
segregation and specificities. Nati Cancer Inst.
Monogr., 36, 139.
OUCHTERLONY, 0. (1949). Antigen antibody reaction in
gels. Acta. Pathol. Microbiol. Scand., 26, 507.
PANGALIS, G.A., NATHWANI, B.N., RAPPAPORT, H. &
ROSEN, A.B. (1979). Acute lymphoblastic leukaemia.
The significance of nuclear convolutions. Cancer, 43,
551.
POPPEMMA, S., ELEMA, J.D. & HALIE, A.R. (1981).
Alkaline phosphatase positive lymphomas: A
morphologic, immunologic and enzyme-histochemical
study. Cancer, 47, 1303.
PORATH, J., AXEN, R. & ERNBACK, S. (1967). Chemical
coupling ofproteins to agarose. Nature, 215, 1491.
TATARINOV, Y.S. (1964). Detection of embryo specific a-
globulin in the blood sera of patients with primary
liver tumour. Vopr. Med. Khim., 10, 90.
WHITESIDE, T.L. & ROWLANDS, T.D. (1977). T-cell and
B-cell identification in the diagnosis of lympho-
proliferative disease. A review. Am. J. Pathol., 88, 754.
YALLOW, R.S. & BERSON, S.A. (1960). Immunoassay of
endogeneous plasma insulin in man. J. Clin. Invest., 39,
1157.